NAD+ at a Glance

• NAD+ is not a peptide. Nicotinamide adenine dinucleotide is a dinucleotide coenzyme, a nicotinamide mononucleotide joined to an adenosine monophosphate through a pyrophosphate bridge. It contains no amino acids and no peptide bonds. The search term “NAD+ peptide” reflects how the compound is catalogued and sold in the research-compound market, not its chemistry.
• Its central role is redox: NAD+ accepts a hydride to become NADH, and the ratio between the two forms is a primary readout of cellular energetic state.
• NAD+ is also consumed not merely cycled. Sirtuins, PARPs and the ectoenzyme CD38 cleave the glycosidic bond and release nicotinamide, which means the pool has to be continuously regenerated through the salvage pathway.
• The claim that NAD+ declines with age is better supported in some tissues than in blood and recent human data have sharpened rather than settled the question.
• Human trials of precursors, nicotinamide riboside and nicotinamide mononucleotide, reliably raise NAD+ metabolite levels. They have been far less consistent on downstream physiological endpoints.
• NAD+ is not an approved drug for any anti-ageing or metabolic indication. Material sold for laboratory work is research-use-only and nothing in this article constitutes dosing guidance.

What Is NAD+, and Why Is “NAD+ Peptide” a Misnomer?

Nicotinamide adenine dinucleotide is catalogued in PubChem as CID 5892, with the molecular formula C₂₁H₂₇N₇O₁₄P₂ and a molecular weight of roughly 663 g/mol. Structurally it is two nucleotides joined tail to tail: a nicotinamide riboside phosphate on one side, an adenosine monophosphate on the other, linked through a pyrophosphate. The nicotinamide ring is the business end. Its positively charged pyridinium nitrogen is what allows the C4 position to accept a hydride ion, and that single reaction underpins most of what NAD+ does in a cell.

The molecule was first described in the early twentieth century as a “coferment” required for yeast fermentation, and it has been a fixture of biochemistry teaching ever since. It is one of the most thoroughly characterised small molecules in biology.

A Naming Problem Worth Stating Plainly

Anyone searching for “NAD+ peptide” will find a large number of product listings and a certain amount of confident-sounding content built around the phrase. The phrase is nonetheless wrong. A peptide is a chain of amino acids joined by amide bonds. NAD+ contains no amino acid residues; the “nicotinamide” in its name refers to the amide of nicotinic acid, a pyridine derivative, not to a peptide linkage.

The term persists for commercial reasons. Research-compound suppliers group NAD+ with genuine peptides, mitochondrial-derived peptides, growth-hormone secretagogues, tissue-repair peptides, because it is bought by the same laboratories, arrives in the same lyophilised vial format, is reconstituted with the same diluents and is subject to the same research-use-only constraints. Catalogue taxonomy has overwritten chemical taxonomy, and search behaviour has followed.

Naming this plainly matters for two reasons. It avoids a category error that propagates into how the compound is handled: NAD+ degradation chemistry is nucleotide chemistry, not peptide chemistry, and the stability considerations differ. And it is a useful marker of how carefully a given source treats the subject. A supplier or article that calls NAD+ a peptide without qualification has not looked closely at the molecule it is describing.

How Does NAD+ Work?

Redox Cofactor and the NAD+/NADH Ratio

The core function is hydride transfer. Hundreds of dehydrogenases use NAD+ as an electron acceptor in catabolic reactions, glycolysis, the tricarboxylic acid cycle, fatty acid beta-oxidation, producing NADH that is reoxidised at complex I of the electron transport chain to drive oxidative phosphorylation.

Because the total pool is finite, the ratio of oxidised to reduced forms rather than the absolute amount determines which direction flux-carrying reactions run. A high NAD+/NADH ratio favours catabolism and oxidation; a low ratio signals reductive stress and constrains glycolytic flux. The ratio differs substantially between the cytosol, the mitochondrial matrix and the nucleus, and these compartments are not freely interchangeable, NAD+ does not readily cross the inner mitochondrial membrane, and shuttles exist precisely because of that.

The Salvage Pathway and NAMPT

NAD+ is not simply recycled between oxidised and reduced states. It is also cleaved, and cleaved frequently. Three families of enzymes hydrolyse the glycosidic bond between the nicotinamide moiety and the ribose, releasing free nicotinamide and consuming the molecule outright.

Vertebrates handle that turnover mainly through the salvage pathway. Nicotinamide phosphoribosyltransferase (NAMPT) converts nicotinamide back to nicotinamide mononucleotide (NMN), and NMN adenylyltransferases (NMNAT1-3) then condense NMN with ATP to regenerate NAD+. NAMPT is the rate-limiting step and the most heavily studied control point in the pathway. Two alternative routes exist, de novo synthesis from tryptophan via the kynurenine pathway, and the Preiss-Handler pathway from nicotinic acid, but in most mammalian tissues salvage carries the bulk of the flux. The comprehensive review by Covarrubias and colleagues (2021, PMID 33353981) sets out the architecture of these routes and their compartmentalisation in detail.

Sirtuins

Sirtuins are NAD+-dependent deacylases, seven of them in mammals, distributed across the nucleus (SIRT1, 6, 7), cytosol (SIRT2) and mitochondria (SIRT3, 4, 5). They remove acetyl and other acyl groups from lysine residues, and in doing so they cleave NAD+ and release nicotinamide. That stoichiometric consumption is what couples their activity to the size of the NAD+ pool: sirtuin activity is not merely regulated by metabolic state, it is metered by it.

The substrates are consequential. SIRT1 deacetylates PGC-1α, FOXO transcription factors and p53; SIRT3 acts on mitochondrial matrix proteins including components of the electron transport chain and of fatty acid oxidation. This is the mechanistic basis for most of the interest in NAD+ as a target in ageing biology, and it is well summarised in the in vivo evidence review by Rajman, Chwalek and Sinclair (2018, PMC6342515).

PARPs and DNA Repair

Poly(ADP-ribose) polymerases, principally PARP1, detect DNA strand breaks and respond by building poly-ADP-ribose chains on target proteins, using NAD+ as the ADP-ribose donor. A single activated PARP1 molecule can consume a great deal of NAD+ quickly, which makes genotoxic stress an acute drain on the pool.

This sets up a direct competition. PARP activation in response to DNA damage depletes the substrate that sirtuins also require, and the trade-off between DNA repair and sirtuin-mediated metabolic regulation is a recurring theme in the literature on ageing and NAD+ availability.

CD38 and NAD+ Consumption

CD38 is a membrane-bound ectoenzyme with NAD+ glycohydrolase activity, expressed on immune cells and upregulated in inflammatory states. Camacho-Pereira and colleagues (2016, PMID 27304511) reported that CD38 expression increases with age in multiple mouse tissues and that CD38 knockout protected against age-related NAD+ decline and mitochondrial dysfunction through a SIRT3-dependent mechanism.

That work reframed the decline question. If NAD+ falls with age, the cause may be increased destruction driven by low-grade inflammation rather than reduced synthesis, a distinction with direct consequences for whether supplying more precursor is the right intervention.

Research Evidence

The Age-Related Decline Literature and How Contested It Is

The proposition that tissue NAD+ falls with age has substantial support in animal models and some support in human tissue. Massudi and colleagues (2012, PMC3407129) measured NAD+ alongside markers of oxidative damage in human tissue samples across a range of ages and reported age-associated changes in NAD+ metabolism. Rodent work has repeatedly found lower NAD+ in aged liver, skeletal muscle and brain.

The human picture has become considerably more complicated. A large analysis published in Nature Metabolism reported that human whole-blood NAD+ levels do not vary with age or with lifestyle interventions (PMID 42135539), directly challenging the use of blood NAD+ as a biomarker of biological ageing. This does not overturn the tissue findings, blood is not muscle, and whole blood is dominated by erythrocytes with their own unusual NAD+ handling, but it does undercut a great deal of the popular framing, and it removes the most convenient measurement from the toolkit.

A 2025 review of NAD+ precursor supplementation in human ageing (PMID 41083806) surveys the clinical evidence and the methodological challenges directly, and its conclusions are notably more cautious than the commercial discourse around the compound. Anyone assessing NAD+ as a research target should read the contested human literature before the mechanistic reviews, not after.

What the Precursor Trials Actually Show

Most human data concern precursors rather than NAD+ itself, and the pattern across them is consistent and instructive: pharmacokinetic endpoints succeed, physiological endpoints largely do not.

Martens and colleagues (2018) administered nicotinamide riboside at 500 mg twice daily for six weeks in a crossover design in healthy middle-aged and older adults, and reported roughly a 60% increase in NAD+ in peripheral blood mononuclear cells with a near-fivefold rise in nicotinic acid adenine dinucleotide as a marker of utilisation. Systolic blood pressure showed a mean reduction of about 3.9 mmHg, which did not reach significance in the full cohort. Elhassan and colleagues (2019, PMID 31412242) found that nicotinamide riboside augmented the aged human skeletal muscle NAD+ metabolome and produced transcriptomic and anti-inflammatory signatures, but without the functional muscle improvements that the mechanistic rationale predicted.

Dollerup and colleagues (2018, PMID 29992272) ran a randomised placebo-controlled trial of nicotinamide riboside in obese men and reported no effect on insulin sensitivity or on lipid mobilisation despite acceptable safety. On the NMN side, Yoshino and colleagues (2021, PMID 33888596) reported increased muscle insulin sensitivity in prediabetic women in Science; that finding attracted a published technical comment and an author response, which is worth reading alongside the original.

Registered trials continue. NCT03821623, for instance, examined nicotinamide riboside for elevated systolic blood pressure and arterial stiffness in middle-aged and older adults. The registry is a better guide to the state of the field than any secondary summary.

Routes of Administration in Research Settings

Because NAD+ itself is a large, charged dinucleotide, its own bioavailability is the central practical question, and the evidence is discouraging for any route that requires the intact molecule to reach a target cell.

Grant and colleagues (2019, PMC6751327) conducted a pilot study of the human plasma and urine NAD+ metabolome during a six-hour intravenous infusion, delivering 750 mg at an infusion rate of 3 µmol/min in eight participants. The striking result was that plasma NAD+ did not accumulate during the first two hours despite continuous infusion; the authors concluded that at that rate NAD+ was “rapidly and completely removed from the plasma for at least the first 2 h.” Plasma NAD+ rose only later in the infusion, while nicotinamide, methylnicotinamide, ADP-ribose and NMN appeared in circulation. The rise in nicotinamide and ADP-ribose in parallel pointed to glycosidic cleavage by ectoenzymes such as CD38.

The interpretation is that intravenous NAD+ largely functions as a way of delivering nicotinamide and other metabolites, because the intact dinucleotide does not survive in circulation or cross plasma membranes intact. Intranasal and subcutaneous routes are discussed in the research-compound market but are supported by far less published pharmacokinetic work than the intravenous route, and no route has been shown to raise intracellular NAD+ in a specific target tissue more efficiently than an orally bioavailable precursor. Cell-surface hydrolysis and the absence of a characterised NAD+ transporter in mammalian plasma membranes are the constraints that any delivery claim has to answer.

What Remains Unknown

Several questions are genuinely open. Whether the tissue-specific NAD+ decline reported in animals is reproducible in human muscle, liver and brain with modern compartment-resolved methods remains unsettled, and the whole-blood data make clear that the measurement matters as much as the finding. Whether raising the NAD+ pool in a tissue translates into altered sirtuin flux, as opposed to altered substrate availability without a change in rate, is not established, because sirtuin activity in vivo is hard to measure directly.

The question of whether CD38 inhibition is a better lever than precursor supply has not been answered in humans. Nor has the dose-response relationship for any precursor been characterised well enough to say whether the trials that failed used too little, treated for too short a period, or selected populations in whom NAD+ was not limiting. Finally, no adequately powered trial has tested exogenous NAD+ itself against an equimolar precursor on a shared endpoint, which is the comparison the research-compound market implicitly assumes has already been made.

Comparison: NAD+ and Its Precursors

A second comparison is worth drawing, because it is the one the research-compound market makes implicitly. NAD+ is frequently grouped with mitochondrial-targeted peptides, and the grouping conflates three different mechanisms.

These are not interchangeable, and a study that treats them as three flavours of the same intervention will produce uninterpretable results. Where a laboratory wants a genuine mitochondrial-derived peptide comparator rather than a coenzyme, MOTS-C peptide is listed as a separate research compound, as is the inner-membrane-targeted tetrapeptide SS-31 peptide. Holding all three to the same documentation standard while keeping their mechanisms distinct in the study design is the useful discipline.

Handling and Reconstitution of Lyophilised NAD+

NAD+ is supplied for research as a lyophilised powder, commonly as the free acid or the disodium salt, and it is chemically more delicate than most of the peptides it sits beside in a catalogue.

The dominant instability is base-catalysed degradation. Wolfe and colleagues (2024) examined the long-term stability of nicotinamide cofactors in common aqueous buffers and reported that the oxidised form, NAD+, degrades under alkaline conditions while the reduced form, NADH, degrades under acidic conditions, with a compromise optimum for holding both near pH 8.5. Buffer identity mattered substantially: at a fixed pH and temperature, Tris preserved the cofactors best, while HEPES and sodium phosphate accelerated degradation several-fold, with phosphate showing a markedly lower activation energy consistent with catalysed breakdown. A temperature rise of only 6 °C, from 19 to 25 °C, roughly tripled degradation rates in two of the three buffers tested.

Three practical consequences follow for bench handling:

• Avoid alkaline drift. Bacteriostatic Water for Injection is mildly acidic, with a labelled pH of 5.7 in a range of 4.5 to 7.0, which sits on the safe side of the NAD+ degradation curve rather than the alkaline side. That is a point in its favour as a diluent for this compound, and the reason bacteriostatic water or an equivalent monographed preserved diluent, listed beside the research compounds themselves at suppliers such as NextGenPeps, is the usual starting point for reconstitution where repeated entry into the vial is planned.
• Keep it cold and keep it dark. NAD+ solutions should be prepared cold, held at 2–8 °C for short-term use and frozen in single-use aliquots for anything longer. Nicotinamide cofactors absorb in the ultraviolet and are photolabile; amber vials or foil wrapping are standard, not fussy.
• Do not cycle freeze-thaw. Aliquot at the point of reconstitution. Repeated thawing of a single vial is the most common avoidable source of drift in a measured concentration.

The mechanical technique is the same as for any lyophilised vial: disinfect the septum with 70% isopropyl alcohol and let it dry, introduce the diluent slowly down the inner wall rather than onto the cake, and swirl gently rather than shaking. Record the resulting concentration in mg/mL, the diluent lot alongside the compound lot, and the date of reconstitution. Because NAD+ degradation produces ultraviolet-absorbing products, a solution that has yellowed or developed haze should be documented and discarded rather than used.

Is NAD+ FDA Approved?

No. NAD+ is not an approved drug in the United States for anti-ageing, metabolic, neurological or addiction-related indications. Nicotinamide and nicotinic acid have long-standing status as vitamins and, in the case of niacin, as an approved lipid-modifying agent, but that does not extend to NAD+ itself, to NMN, or to any parenteral NAD+ preparation.

Intravenous NAD+ infusions marketed by wellness clinics are compounded preparations rather than approved products, and the FDA’s compounding framework is the relevant context. The agency’s list of certain bulk drug substances that may present significant safety risks includes withdrawn nominations for a number of research peptides, with stated concerns about immunogenicity, peptide-related impurities and active pharmaceutical ingredient characterisation. NMN’s regulatory position as a dietary ingredient has also been contested in the United States, and its status has shifted over time.

The position for a laboratory is straightforward. NAD+ purchased as a research compound is research-use-only material. It is not a medicine, its supplier is not making a therapeutic claim, and the absence of approval means that identity and purity documentation carries the entire evidentiary burden that a marketing authorisation would otherwise carry.

Where to Source Research-Grade NAD+

Because no regulatory approval underwrites the material, documentation is the only signal available. The following is what a defensible purchase record looks like.

• A lot-matched certificate of analysis referencing the specific lot shipped rather than a representative batch.
• Third-party HPLC purity data with a named laboratory and a test date. For NAD+ specifically, the assay should resolve nicotinamide and other degradation products, because those are what a poorly stored lot will contain.
• Mass spectrometry confirming identity and molecular weight. Purity figures without identity confirmation do not establish that the correct compound is in the vial.
• The salt form stated on the label free acid or disodium salt, because it changes the mass of active compound per stated milligram.
• Declared water content or a Karl Fischer figure since residual moisture in a lyophilised nucleotide accelerates degradation in storage.
• Cold-chain and light-protective packaging appropriate to a photolabile, base-sensitive compound.
• Explicit research-use-only labelling with no dosing guidance, no suggested protocol and no human-use framing anywhere in the listing.

The red flags are mostly absences and overreaches. A certificate with no laboratory name, no date or no lot reference is decoration rather than evidence. A supplier that cannot say which salt form is in the vial cannot tell you how much compound you bought. Any listing that offers a human protocol, an infusion schedule or a therapeutic indication has stepped outside the research-use-only frame and should be read as a compliance problem rather than a service. And because this compound is mis-sold under a chemically incorrect label across much of the market, a supplier’s willingness to describe it accurately is itself informative. Catalogues that list NAD+ peptide as a research compound can be assessed on exactly these terms: lot-matched documentation, a named testing laboratory, a stated salt form, and research-use-only labelling without protocol content.

Frequently Asked Questions

Is NAD+ actually a peptide?

No. NAD+ is a dinucleotide coenzyme with no amino acids and no peptide bonds. The term “NAD+ peptide” is a market artefact arising from the way research-compound suppliers group products, and it has been reinforced by search behaviour. The chemistry is nucleotide chemistry, which matters because the degradation pathways and handling requirements differ from those of a true peptide.

What is the difference between NAD+, NMN and NR?

They sit at different points on the same pathway. NAD+ is the coenzyme itself. NMN is one enzymatic step away, requiring only adenylylation by NMNAT. NR is a nucleoside two steps away, phosphorylated by nicotinamide riboside kinase to NMN and then converted to NAD+. NR has the best-established oral bioavailability of the three; NAD+ itself has the worst.

Does NAD+ decline with age?

Tissue data in animals fairly consistently show a decline, and some human tissue work points the same way. A large recent analysis reported that human whole-blood NAD+ levels do not vary with age or with lifestyle interventions, which challenges blood as a biomarker without settling the tissue question. The honest summary is that the direction of the effect is plausible and the magnitude, tissue distribution and measurement method are all still contested.

Why is intravenous NAD+ studied if oral precursors work?

The rationale is that supplying the intact coenzyme bypasses the salvage pathway. The pharmacokinetic evidence does not support that rationale well: in a six-hour infusion study the plasma NAD+ concentration did not rise for the first two hours while nicotinamide and ADP-ribose appeared in circulation, consistent with extracellular hydrolysis. Intravenous NAD+ appears to function largely as a nicotinamide delivery route.

Do sirtuins actually consume NAD+?

Yes, stoichiometrically. Each deacylation reaction cleaves NAD+ and releases nicotinamide, which is what couples sirtuin activity to the size of the NAD+ pool rather than merely to metabolic signalling. The same is true of PARPs and of CD38, and the three families compete for the same substrate.

What does CD38 have to do with NAD+ decline?

CD38 is an NAD+-consuming ectoenzyme whose expression rises with age and with inflammation. Work in mice reported that CD38 knockout protected against age-related NAD+ decline and mitochondrial dysfunction through a SIRT3-dependent mechanism, which suggests the decline may be driven by increased destruction rather than reduced synthesis, a distinction that matters for whether precursor supply is the right lever.

How should lyophilised NAD+ be stored?

Cold, dry and dark. The lyophilised powder is the stable form and should be held refrigerated or frozen with light protection. Reconstituted solutions are prepared cold, held at 2–8 °C for short-term use, aliquoted for anything longer, and kept out of light. NAD+ is base-sensitive, so alkaline conditions should be avoided.

Why does buffer choice matter for NAD+ in solution?

Because degradation is catalysed differently in different buffers. Published stability work found Tris preserved nicotinamide cofactors best, while HEPES and sodium phosphate accelerated degradation several-fold at the same pH and temperature, with phosphate showing a distinctly lower activation energy. Buffer identity is a real experimental variable, not a formality.

Is NAD+ approved for any use?

No. NAD+ is not an approved drug for any indication. Nicotinamide and nicotinic acid have separate status as vitamins, and niacin has an approved lipid-modifying use, but none of that transfers to NAD+, to NMN, or to parenteral NAD+ preparations, which are compounded rather than approved products.

What does research-use-only mean in practice for NAD+?

It means the material is sold for laboratory investigation, the supplier makes no therapeutic claim, and no human or veterinary use is contemplated or supported. It also means no marketing authorisation underwrites identity or purity, so lot-matched analytical documentation is the only evidence available that the vial contains what the label says.

The Bottom Line

NAD+ is one of the best-characterised molecules in biochemistry and one of the least well-characterised interventions in ageing research. The mechanistic case is genuinely strong: a finite, continuously consumed coenzyme sits at the intersection of redox metabolism, sirtuin-mediated regulation, DNA repair and inflammatory signalling, and it is hard to construct a cellular process that does not touch it somewhere.

The translational case is much weaker than the mechanistic one, and the gap is where most of the confusion lives. Precursor trials raise NAD+ metabolites reliably and move physiological endpoints inconsistently. Whole-blood measurements have turned out not to track age. The intact dinucleotide does not survive in circulation well enough for its own delivery to be straightforward. And the compound is sold across much of the research market under a chemically incorrect label, which is a reasonable proxy for how carefully the surrounding claims have been checked.

For a laboratory, the useful posture is to treat NAD+ as what it is: a well-understood coenzyme, a contested intervention, and a research compound whose provenance has to be documented because nothing else vouches for it. Get the chemistry right, get the salt form and the storage right, read the negative trials alongside the positive ones, and keep the mechanistic distinctions between a coenzyme and a mitochondrial peptide intact in the study design.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

The compounds discussed in this article are intended for laboratory research use only. NAD+ is not approved by the U.S. Food and Drug Administration or any comparable regulatory authority for the diagnosis, treatment, cure or prevention of any disease. Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it should be interpreted as a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind.

Research compounds described here are not for human or veterinary use. Where findings from the published literature are described, they are reported as they appear in the cited in vitro, animal or clinical work and should not be extrapolated beyond the populations and conditions studied; doses and concentrations quoted from that literature are reported in the terms the original investigators used and are not recommendations. Readers with clinical questions should consult a qualified healthcare professional. Readers are responsible for compliance with all applicable laws, institutional review requirements and biosafety regulations in their jurisdiction.

Stay updated, free articles. Join our Telegram channel

Join